Polo-like kinase inhibitors
    1.
    发明授权
    Polo-like kinase inhibitors 失效
    马球状激酶抑制剂

    公开(公告)号:US08202990B2

    公开(公告)日:2012-06-19

    申请号:US12680142

    申请日:2008-09-25

    IPC分类号: C07D487/04

    摘要: The present invention relates generally to processes of making 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide and Form A of 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide.

    摘要翻译: 本发明一般涉及制备4-(9-环戊基-7,7-二氟-5-甲基-6-氧代-6,7,8,9-四氢-5H-嘧啶并[4,5-b] [1,4]二氮杂-2-基氨基)-3-甲氧基-N-(1-甲基哌啶-4-基)苯甲酰胺和4-(9-环戊基-7,7-二氟-5-甲基-6 - 氧代-6,7,8,9-四氢-5H-嘧啶并[4,5-b] [1,4]二氮杂-2-基氨基)-3-甲氧基-N-(1-甲基哌啶-4-基) 苯甲酰胺。

    Indazole benzimidazole compounds
    9.
    发明申请
    Indazole benzimidazole compounds 失效
    吲唑苯并咪唑化合物

    公开(公告)号:US20060079564A1

    公开(公告)日:2006-04-13

    申请号:US11261995

    申请日:2005-10-27

    IPC分类号: A61K31/4184 C07D403/04

    CPC分类号: C07D403/04

    摘要: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.

    摘要翻译: 提供具有结构I的有机化合物,其中变量具有本文所述的值。 抑制患者中c-ABL的方法包括向患者施用有效量的结构I化合物,化合物的互变异构体,化合物的药学上可接受的盐或互变异构体的药学上可接受的盐。